Can-Fite BioPharma
AboutSciencePipelineInvestor InformationContact Us

Pipeline

Pipeline

Overview
CF101
CF102
CF602
 

Overview

Can-Fite has a number of drugs in various stages of research and development. The pipeline drugs are synthetic, highly specific agonists and an allosteric modulator, all target the A3 adenosine receptor. All drugs are orally bioavailable with an excellent safety profile.

 

Piclidenoson (CF101), Can-Fite’s first candidate, is an oral drug that has been successfully tested in animal models and is currently in Phase III clinical studies for the treatment of Rheumatoid Arthritis (RA) and Psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile. In two Phase II studies where Piclidenoson has been given as a standalone drug, data indicated that it acted as a disease modifying anti-inflammatory drug in RA patients. The Phase II the Phase II/III clinical studies in Psoriasis clinical activity and safety of the drug. 

 

 

Committed to develop highly
specific life changing drugs


Namodenoson (CF102), Can-Fite’s second drug candidate, is an oral drug currently being developed for the treatment of Liver Diseases including hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH).
 

CF602, an allosteric modulator at the A3AR which has shown proof of concept in pre-clinical pharmacology studies and is earmarked for the treatment of sexual dysfunction.